APMAP Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. In this model, the APMAP gene has been disrupted using CRISPR/Cas9-mediated genome editing, resulting in a heterogeneous pool of cells carrying targeted gene knockout events. This polyclonal format provides a robust and cost-effective loss-of-function tool for studying APMAP-dependent processes in an intestinal epithelial context. The edited population is suitable for a broad range of cellular and molecular assays without requiring clonal isolation.
The HT29 cell line, originally derived from a female patient with colorectal adenocarcinoma, serves as a well-established in vitro model for intestinal epithelial biology and colorectal cancer research. HT29 cells retain key features of intestinal epithelium and are widely used to investigate colorectal tumorigenesis, cellular differentiation, and barrier function. Their adherent growth and well-characterized signaling networks make them particularly suitable for studying the roles of cell adhesion molecules and glycobiology. The APMAP knockout in this background allows direct interrogation of gene function in a disease-relevant setting.
APMAP encodes a transmembrane C-type lectin that mediates cell adhesion and carbohydrate recognition. It has been implicated in endocytosis and angiogenesis regulation, interacting with BAI1 and potentially modulating downstream actin cytoskeleton reorganization. While upstream regulators remain poorly defined, APMAP is thought to function in complexes with MAGI scaffolding proteins and carbohydrate ligands. Through these interactions, APMAP may influence cell signaling cascades controlling adhesion and migration. The knockout of APMAP disrupts these molecular networks, providing a clean background to dissect its role in carbohydrate-dependent recognition and downstream effector pathways.
In the colorectal cancer context, APMAP loss of function provides insights into the molecular determinants of tumor cell adhesion and invasion. Given HT29 cells’ utility in studying intestinal epithelial integrity, this knockout model enables exploration of how APMAP contributes to colorectal adenocarcinoma progression through altered cell-extracellular matrix interactions and carbohydrate-binding properties. Its role in angiogenesis regulation further positions APMAP as a potential node linking metabolic disorders and cancer. Thus, the APMAP knockout HT29 polyclonal cells are a valuable tool for investigating the intersection of glycosylation, cell adhesion, and oncogenic signaling.
Typical applications include cell adhesion and migration assays to quantify changes in the loss of APMAP, as well as co-immunoprecipitation and lectin binding assays to probe its carbohydrate recognition partners. Western blotting and immunofluorescence can confirm protein expression changes in associated pathways. The model is also suited for drug target validation studies in colorectal cancer, particularly compounds targeting C-type lectins or adhesion modulators. Functional rescue experiments can be performed to confirm APMAP-dependent phenotypes. For detailed protocols and ordering information, please contact Ascent Research.
